Molbio targets FY28 veterinary launch with companion assays
Key highlights
- Molbio expects its initial new veterinary diagnostics products to reach the market in FY28.
- Molbio already sells one rabies product and is developing two of six additional veterinary assays.
- The first veterinary phase targets companion animals with tests including parvo, canine distemper and leptospirosis.
- Molbio said close to 10,000 Truenat machines are installed in government primary centres for human diagnostics, not veterinary use.
powered by IRIS

Molbio plans to bring initial veterinary diagnostics products to market in FY28, starting with companion-animal tests for parvo, canine distemper and leptospirosis. Management said one rabies product is already marketed, while two of the remaining six planned assays are in development and testing.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
What is Molbio planning in veterinary diagnostics?
Molbio is creating a veterinary diagnostics business centred initially on companion animals rather than livestock, with FY28 identified as the expected market-entry point for new assays. Management said it already sells a rabies product and is building six additional offerings, of which two assays have entered development and testing.
The initial disease menu is intended to address commonly encountered companion-animal conditions, including parvo, canine distemper and leptospirosis. Management did not identify the complete six-assay menu or provide expected prices, sales targets or capital expenditure for the vertical. It said work on the other four assays will start after the first two development programmes progress.
Why is Molbio starting with companion animals?
Molbio is starting with dogs and cats because management sees companion animals as the initial customer segment for point-of-care testing. It said veterinarians often treat pets based on symptoms rather than diagnostic data, creating a gap for tests performed at the clinic instead of being sent elsewhere.
Management described the veterinary molecular-testing market as unorganised and said no separate Indian market-size estimate is available for molecular diagnostics. According to Molbio, few veterinary hospitals or clinics have their own molecular devices, while tests requiring molecular analysis are generally sent to centralised laboratories and can become expensive.
The first phase therefore differs from a livestock-led approach involving cattle, poultry or swine. Management said Molbio may move later into bovine testing and shrimp applications, but named no schedule for those categories. It also said veterinary diseases do not currently have a notifiable-disease framework comparable with human tests such as tuberculosis or COVID-19.
That distinction affects the stated route to market. Rather than positioning the initial veterinary portfolio around government-mandated reporting or surveillance, management is seeking to establish a clinic-level companion-animal segment. It characterised the opportunity as market creation, rather than an effort to take share from a defined molecular-testing market or a named incumbent.
Which Molbio platforms will support veterinary testing?
Molbio expects its Truenat platform to carry a growing suite of veterinary assays, while its Truecyte platform is intended for both human and veterinary use. Management said veterinary studies involving Truecyte have already begun and their results are promising, with validation expected to follow.
Truenat is Molbio’s existing multi-disease diagnostic platform. In the human business, management said the platform continues to expand from tuberculosis into hepatitis, human papillomavirus, or HPV, and other applications. The veterinary plan applies the same approach of adding disease-specific assays over time, beginning with a seven-product suite that includes the marketed rabies test.
Radiology is already part of the veterinary offering, according to management, although the call did not provide product specifications, revenue or installation figures for that activity. Molbio described the planned suite as radiology, rabies testing, additional Truenat assays and potential Truecyte veterinary uses, rather than as a single instrument launch.
Truecyte was also discussed as a platform for cell morphology and cell counts in human settings. Management said its veterinary studies are separate from Molbio’s human diagnostic applications, but did not disclose the veterinary indications, study size, validation timetable or regulatory requirements for animal use.
Got a follow-up? Ask IRIS
When will Molbio’s veterinary assays reach the market?
Molbio expects its initial new veterinary assays to enter the market in FY28 after generating initial data and completing analytical studies. Management said two of the six assays beyond rabies are in development and testing, making FY28 a commercial expectation rather than a product already available for sale.
The disclosed sequence is that Molbio will create assays for the first two diseases, obtain initial data, proceed to analytical studies and then start the other four assays. The company did not state whether all six new assays will launch simultaneously in FY28, whether each requires separate validation, or whether tests will be introduced in stages during that financial year.
Management’s timing is distinct from the process outlined for three new human-diagnostics platforms, where it expects a Central Drugs Standard Control Organisation, or CDSCO, manufacturing-and-sale licence process to take about four or five months. No corresponding veterinary regulatory timeline was supplied for the companion-animal assays, so the FY28 estimate should not be read as a disclosed approval date.
The FY28 timeframe also sits alongside, rather than replacing, Molbio’s human diagnostics plans. Management said its Truenat expansion, including hepatitis and HPV applications, its screening platform Truepoc, syndromic-testing platform Trueamp and veterinary vertical will run in parallel, with resources allocated to each business.
How could Molbio sell veterinary point-of-care tests?
Molbio intends to address veterinary clinics with point-of-care diagnostics that reduce reliance on centralised laboratories, according to management. The company said it sees a need for more organised and convenient clinic solutions, particularly where veterinarians now lack on-site molecular testing.
This model differs from Molbio’s government-led human diagnostic business. Management said close to 10,000 Truenat machines are installed in government primary centres for human diagnostics, and government rate contracts can run for two years after price negotiations. No comparable installed-base figure, procurement framework or distributor plan was provided for veterinary clinics.
Management did not quantify the addressable veterinary market, expected market share over three to five years, expected assay utilisation or the vertical’s prospective revenue contribution. It said the purpose is to create a new segment in veterinary point-of-care molecular testing, where it believes Truenat could be among the first few products in the market.
Molbio also gave no specific plan for whether companion-animal tests will be sold directly to clinics, through distributors or through veterinary hospital chains. Its comments instead focused on the clinical mechanism: faster data at the point of care could give veterinarians diagnostic information before deciding treatment, rather than relying only on visible symptoms.
Conclusion
Molbio’s disclosed strategy extends its diagnostics portfolio into a new companion-animal segment while retaining its existing human-diagnostics expansion. The seven-product veterinary suite includes marketed rabies testing, six planned additional assays, radiology and possible Truecyte use, but management has not quantified its potential revenue, market size, pricing or market share.
The next milestones are initial data and analytical studies for the first two new assays, followed by development of the other four and the planned FY28 market entry. Investors will also need to watch for management disclosures on assay-specific launch timing, veterinary validation, sales channels and the contribution of the new vertical after launch.


